In this episode, Drs. Erin Michos and Gissette Reyes-Soffer discuss how clinicians can manage elevated Lp(a) by treating all modifiable factors in patients. The global risk assessment of patients and what can be done now to navigate and mitigate risk is also addressed.

This CardiaCast episode is part of an ACC course titled Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap. Educational grant support is provided by Novartis. To visit the Online Course page for the Elevating Lp(a) Awareness: Bridging the CVD Risk Knowledge Gap Grant, click here!

Related References:

1. Reyes-Soffer G, Yeang C, Michos ED, Boatwright W, Ballantyne CM. High lipoprotein(a): actionable strategies for risk assessment and mitigation. Am J Prev Cardiol 2024;18:100651.
2. Tsimikas S, Fazio S, Ferdinand KC, Ginsberg HN, Koschinsky ML, Marcovina SM, et al. NHLBI Working Group recommendations to reduce lipoprotein(a)-mediated risk of cardiovascular disease and aortic stenosis. J Am Coll Cardiol 2018;71:177-92.
3. Reyes-Soffer G, Ginsberg HN, Berglund L, Duell PB, Heffron SP, Kamstrup PR, et al; on behalf of the American Heart Association Council on Arteriosclerosis, Thrombosis and Vascular Biology; Council on Cardiovascular Radiology and Intervention; and Council on Peripheral Vascular Disease. Lipoprotein(a): a genetically determined, causal, and prevalent risk factor for atherosclerotic cardiovascular disease: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol 2022;42:e48-e60.
4. Koschinsky ML, Bajaj A, Boffa MB, et al. A focused update to the 2019 NLA scientific statement on use of lipoprotein(a) in clinical practice. J Clin Lipidol 2024;Mar 29:[ePub ahead of print].